Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
Executive Summary
The rapidly evolving stem cell space may have matured to the level where a single company's misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following the mixed results of Osiris Therapeutics' Prochymal stem cell therapy in an interim look at a study in chronic obstructive pulmonary disease.
You may also be interested in...
iZumi & Pierian Join Forces to Advance EMerging iPS Cell Platform
Every so often an undeniably important technology emerges resulting in the consolidation of IP and the alignment of thought leaders around a few main players. The new battleground is stem cells. And though the two heavy hitters in the promising induced pluripotent stem (iPS) cell space, Ipierian and Fate Therapeutics, are perhaps less aggressive in publicly asserting their dominance, they've positioned themselves as leading competitors in the still-nascent but rapidly advancing area of cellular reprogramming.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.